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Abstract
Background: Recently, natural products have been evaluated as sources of antimicrobial agents
with efficacies against a variety of micro-organisms.
Methods: This report describes the antimicrobial activities of pomegranate rind extract (PRE)
singularly and in combination with cupric sulphate against methicillin-sensitive and -resistant
Staphylococcus aureus (MSSA, MRSA respectively), and Panton-Valentine Leukocidin positive
community acquired MSSA (PVL positive CA-MSSA).
Results: PRE alone showed limited efficacy against MRSA and MSSA strains. Exposure to copper
(II) ions alone for 2 hours resulted in moderate activity of between 102 to 103 log10 cfu mL-1
reduction in growth. This was enhanced by the addition of PRE to 104 log10 cfu mL-1 reduction in
growth being observed in 80% of the isolates. However, the PVL positive CA-MSSA strains were
more sensitive to copper (II) ions which exhibited moderate activities of between 103 log10 cfu mL-
1 reduction in growth for 60% of the isolates.
Conclusion: PRE, in combination with Cu(II) ions, was seen to exhibit moderate antimicrobial
effects against clinical isolates of MSSA, MRSA and PVL positive CA-MSSA isolates. The results of
this study indicate that further investigation into the active ingredients of natural products, their
mode of action and potential synergism with other antimicrobial agents is warranted. This is the
first report of the efficacy of pomegranate against clinical PVL positive CA-MSSA isolates.
Background
Considerable emphasis is being placed on combating
multi-drug resistant bacteria in the clinical setting. These
proposed infection control measures encompass the study
of hospital cleaning measures, prevention of transmission
by healthcare workers and the development of new anti-
microbial agents [1-3]. During the year beginning in April
2005, methicillin resistant Staphylococcus aureus (MRSA)
bacteraemia cases in England totalled 7,087 [4]. Methicil-
lin sensitive Staphylococcus aureus (MSSA) are also resistant
to multiple antibiotics [5], however these isolates respond
better to treatment than MRSA counterparts. The commu-
nity acquired MSSA (CA-MSSA) can produce the Panton-
Valentine Leukocidin (PVL) toxin which is of particular
concern as infections with these organisms have resulted
in increased levels of morbidity and mortality [6].
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Recently, studies have been redirected towards evaluating
traditional medicines as sources of antimicrobial agents
[7-10]. A wide range of natural products have been
screened for activity against S. aureus, including the pome-
granate (Punica granatum). In a study by Machado et al.
[11] various extracts of pomegranates (in ethanol, chloro-
form, ethyl acetate, butanol and water) all exhibited activ-
ities against MSSA and MRSA. A further study by Braga et
al. [12] demonstrated the inhibition of growth and release
of enterotoxin by some S. aureus isolates.
Numerous metal containing-antimicrobial agents have
been reported despite advanced protective mechanisms
for the detoxification of heavy metal ions being found in
many bacteria [13]. The enhancement of the anti-bacteri-
ophage and antimicrobial activities exhibited by pome-
granate rind extracts (PRE) by the addition of metal ions
has been reported [14,15]. Stewart et al. reported remark-
able anti-bacteriophage activities for the combination of
pomegranate rind extracts with ferrous salts. However,
this combination was found to exhibit activity for a short
period probably owing to instability. Previous work car-
ried out by the current authors demonstrated that PRE, in
combination with different metals, showed an antibacte-
rial effect against a range of laboratory strains of both
Gram positive and negative bacteria [15]. This study
showed that PRE with the addition of CuSO4 demon-
strated inhibitory effects against three Gram negative
strains of bacteria: Pseudomonas aeruginosa (NCTC 950),
Proteus mirabilis (NCTC 7827) and Escherichia coli (NCTC
12241), with kill rates from 108 cfu mL-1 to no detectable
growth within 30 minutes. Against S. aureus this combina-
tion (PRE/CuSO4) reduced the bacterial population by
approximately 102cfu mL-1; however, the addition of a
stabilising agent (vitamin C) to the combination resulted
in no detectable growth after 30 minutes.
The aim of this study was to explore the potential role for
the PRE/Cu(SO4) with the addition of a stabilising agent
against clinical isolates of S. aureus. Thirty isolates were
tested which included MRSA (n = 10), MSSA (n = 10) and
PVL positive CA-MSSA (n = 10).
Methods
Preparation of pomegranate rind extract
Pomegranate rind extract (PRE) was prepared by cutting
rind into small squares (approximately 5 mm2) which
were dried at 55°C for 24 hours, and stored in an air tight
container in the dark until further use. A 10 g sample of
dry rind was added to 150 mL distilled water and placed
in a shaker (at 80 rpm) at room temperature for 24 hours
[9]. The crude extract was passed though muslin and a
Whatman filter No.1 to remove the particulate matter,
prior to filter sterilising by passing through a 0.2 μm filter
(Millipore), into a sterile bottle. The extract was stored at
-20°C for future use.
Bacterial isolates
Clinical isolates of MRSA (n = 10), MSSA (n = 10) and PVL
positive CA-MSSA (n = 10) were used in the study. The
MRSA and MSSA isolates were collected from the Royal
Marsden hospital (London, UK) and the PVL positive CA-
MSSA isolates were collected from the Devon and Exeter
hospital (UK). Identification of all isolates was deter-
mined by Gram stain and Staphylase Test (Oxoid, UK)
which were conducted in house. The isolates were cul-
tured aerobically overnight on nutrient agar (Oxoid) at
37°C and then frozen in cryovials (Pro-labs, UK) at -80°C
until required. Prior to use all isolates were passaged twice
on nutrient agar aerobically at 37°C. In all assays inocula
were prepared by using overnight cultures on nutrient
agar that were then suspended in Ringer's solution
(Oxoid) to a turbidity equivalent to 0.5 McFarland (1.5 ×
108 cfu mL-1).
Antibiotic sensitivity testing
The three groups of bacteria were tested against a specific
panel of antibiotics for that group, in house, using stand-
ard operating procedures defined by the British Society for
Antimicrobial Chemotherapy [16]. All antibiotics were
purchased from MAST diagnostic (UK). The MRSA and
MSSA isolates were tested against cefotixitin (10 μg), pen-
icillin (1 unit), erythromycin (5 μg), gentamicin (10 μg),
rifampicin (2 μg), cancomycin (5 μg), mupirocin (5 μg)
and cefuroxime (5 μg). The PVL CA-MSSA isolates were
tested against penicillin (1 unit) and methicillin (5 μg).
Antimicrobial activity of PRE with the addition of cupric 
sulphate
All reagents were purchased from Sigma-Aldrich Chemi-
cal Co. (Poole, Dorset) and distilled water was used as
diluent throughout. The method used was an adaptation
of that described by McCarrell et al. [15]. Briefly, overnight
cultures on nutrient agar were suspended in Ringer's solu-
tion (Oxoid) to a turbidity equivalent to 0.5 McFarland
(1.5 × 108 cfu mL-1). An aliquot of the PRE extract (330
μL) was added to 700 μL of the freshly prepared solutions
(4.8 mM) of cupric sulphate (CuSO4,); the final solution
was protected from light [15].
The appropriate bacterial dilution was prepared and 50 μL
placed in a sterile Eppendorf micro-centrifuge tube (SLS,
UK) with 100 μL of the extract/metal salt solution
(Lambda buffer used for control). Following incubation
of the sample for 2 hours at room temperature, the activity
of the bactericidal agent was neutralized by adding an
equal volume of 2% (v/v) Tween-80 (Sigma-Aldrich
Chemical Co., UK) in Lambda buffer [15]. Serial dilutions
were prepared in Ringer's solution, 10 μL of each dilution
was spotted onto a nutrient agar plate and incubated aer-
obically for 24 hours at 37°C. Each assay was carried out
in triplicate.BMC Complementary and Alternative Medicine 2009, 9:23 http://www.biomedcentral.com/1472-6882/9/23
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Antimicrobial activity of PRE and cupric sulphate with the 
addition of different concentrations of vitamin C
The antimicrobial assay was carried out as previously
stated McCarrell et al., [15] with the following modifica-
tion. Before adding the cupric salt solution to PRE, vita-
min C was added to the cupric salt. Varying
concentrations of vitamin C were added to the copper(II)
salt solution, comprising the following ratios; 1:1 (4.8
mM), 1:5 (24 mM), 1:20 (96 mM) (cupric salt: vitamin
C), 700 μL of which was added to PRE.
Minimum inhibition concentration (MIC) determination of 
PRE and CuSO4
Micro-dilution plates were prepared with freeze-dried PRE
or CuSO4solution which was added to sterile water at a
concentration of 800 mg mL-1. The plates were prepared
as follows; 50 μL of four-times strength Iso-Sensitest broth
(Oxoid, UK) was added to the first row (A) of wells and
50 μL of double strength Iso-Sensitest broth was added to
all remaining wells. To the first row of wells 50 μL of the
PRE was added and mixed, 50 μL of broth from row A was
transferred to row B and mixed, this process was contin-
ued to row F. Finally, 50 μL of broth was removed from
well F and discarded. The overnight cultures were sus-
pended in Ringer's solution to a turbidity of 0.5 McFar-
land (1.5 × 108 cfu mL-1). A 50 μL aliquot of suspension
was added to well A (final concentration of PRE in well A
= 200 mg mL-1) through to G. All samples were carried out
in triplicate. All plates were incubated at 37°C for 24
hours. After incubation 10 μL of broth from each well was
spotted onto nutrient agar and incubated at 37°C for 24
hours. After incubation the plates were examined to deter-
mine breakpoints by the presence or absence of growth.
Minimum inhibition concentration determination of PRE/
CuSO4 combination
The assay was carried out as described above with the fol-
lowing changes: PRE and CuSO4 were prepared as before
but using four times concentration of half the determined
MIC. Addition of the CuSO4 was made to the PRE suspen-
sion instead of sterile water.
Results
Antimicrobial testing
Antibiotic sensitivity profiles were first determined for the
clinical isolates and the MRSA isolates were on average
Table 1: Antibiotic resistances profile for the S. aureus tested.
Isolates Source Antibiogram
Methicillin-resistant Staphylococcus aureus 1 BW Fluclox, Pen, CXM
Methicillin-resistant Staphylococcus aureus 2 WS Fluclox, Pen, Ery, CXM
Methicillin-resistant Staphylococcus aureus 3 NS Fluclox, Pen, Ery, Gent, CXM
Methicillin-resistant Staphylococcus aureus 4 SPT Fluclox, Pen, Ery, CXM
Methicillin-resistant Staphylococcus aureus 5 NS Fluclox, Pen, Ery, CXM
Methicillin-resistant Staphylococcus aureus 6 WS Fluclox, Pen, Ery, Gent, CXM
Methicillin-resistant Staphylococcus aureus 7 WS Fluclox, Pen, Ery, CXM
Methicillin-resistant Staphylococcus aureus 8 WS Fluclox, Pen, Ery, CXM
Methicillin-resistant Staphylococcus aureus 9 NS Fluclox, Pen, Ery, CXM
Methicillin-resistant Staphylococcus aureus 10 U Fluclox, Pen, Ery, CXM
Methicillin-sensitive Staphylococcus aureus 1W S P e n
Methicillin-sensitive Staphylococcus aureus 2W S P e n
Methicillin-sensitive Staphylococcus aureus 3W S P e n
Methicillin-sensitive Staphylococcus aureus 4W S P e n
Methicillin-sensitive Staphylococcus aureus 5W S P e n
Methicillin-sensitive Staphylococcus aureus 6W S P e n
Methicillin-sensitive Staphylococcus aureus 7W S P e n
Methicillin-sensitive Staphylococcus aureus 8W S P e n
Methicillin-sensitive Staphylococcus aureus 9W S P e n
Methicillin-sensitive Staphylococcus aureus 10 WS Pen
PVL producing CA-MSSA 1 WS Pen
PVL producing CA-MSSA 2 WS Pen
PVL producing CA-MSSA 3 WS Pen
PVL producing CA-MSSA 4 WS Pen
PVL producing CA-MSSA 5 WS Pen
PVL producing CA-MSSA 6 WS Pen
PVL producing CA-MSSA 7 WS Pen
PVL producing CA-MSSA 8 WS Pen
PVL producing CA-MSSA 9 WS Pen
PVL producing CA-MSSA 10 WS Pen
KEY for source: BW: breast wound; WS: wound swab; NS: nose swab; U: urine; SPT: sputum.
Key for antibiotics: cefotixitin (Fluclox), penicillin (Pen), erythromycin (Ery), gentamicin (Gent), cefuroxime (CXM),BMC Complementary and Alternative Medicine 2009, 9:23 http://www.biomedcentral.com/1472-6882/9/23
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resistant to four of the eight antibiotics tested (Table 1).
All of the MSSA isolates and the PVL positive CA-MSSA
were resistant only to penicillin.
Antimicrobial activity of PRE with addition of cupric 
sulphate
For the MRSA isolates, the PRE on its own exhibited no
activity (Figure 1). In contrast, the copper (II) ions had
some activity of between 102 to 103 log cfu mL-1 reduction
in growth. However, the PRE/Cu (II) combination exhib-
ited an enhanced activity of 104 log10 cfu mL-1 reduction in
growth observed in 50% of the isolates. No detectable
level of growth was determined for one isolate; however,
a similar result was obtained for the Cu(II) on its own.
Similar results were observed for the MSSA isolates, with
no discernable effect being observed for the PRE alone
(Figure 2). However, Cu(II) alone demonstrated a mean
reduction of 102 log10 cfu mL-1, although four of the iso-
lates showed a reduction of 104 log10 cfu mL-1and one iso-
late recorded no detectable growth. The combination of
PRE/Cu(II) showed a mean reduction of 104 log10 cfu mL-
1 with only two isolates exhibiting no detectable growth.
However, one of these isolates also had no detectable
growth with Cu(II) alone.
For the PVL positive CA-MSSA isolates, once again the PRE
alone had no activity against any isolates studied. In con-
trast to the MSSA and MRSA, the PVL positive CA-MSSA
isolates were more sensitive to copper (II) ions which
exhibited a moderate reduction in growth of 103 log cfu
mL-1 for 60% of the isolates. Notably, for the remaining
40% of the isolates, less reduction in growth indicated less
sensitivity to Cu(II) ions; however, the addition of PRE
reduced the growth in these 40% in line with the copper-
sensitive 60% (Figure 3).
Antimicrobial activity of PRE and metal salts with the 
addition of different concentrations of vitamin C
The combination of Cu (II) sulphate and vitamin C exhib-
ited a reduction in growth of 104 log10 cfu mL-1 compared
to the buffer control (data not shown). The addition of
vitamin C to the PRE/Cu(II) compound demonstrated
similar results to Cu (II) sulphate and vitamin C mixture
(data not shown).
Minimum inhibition concentration determination of PRE 
and CuSO4
Determination of the MIC of PRE and CuSO4 individually
and in combination are shown in Table 2: PRE had an
MIC between 25.0–12.5 mg mL-1 for all isolates tested.
The MIC of CuSO4 alone ranged from 3.12–0.78 mg mL-
1, with a mode concentration of 1.56 mg mL-1. The com-
bination of PRE: Cu(II) against all isolates of S. aureus
resulted in values which were half or a quarter of the MIC
of PRE or CuSO4 alone. Thus, an additive effect was seen
against all groups of S. aureus for the combination.
Box Whisker statistical analysis of the viable count data  achieved in relation to the antimicrobial activities of PRE  alone and in combination with Cu(II) ions after a 2 hour incu- bation against 10 clinical isolates of MRSA using Lambda  buffer as a control Figure 1
Box Whisker statistical analysis of the viable count 
data achieved in relation to the antimicrobial activi-
ties of PRE alone and in combination with Cu(II) ions 
after a 2 hour incubation against 10 clinical isolates of 
MRSA using Lambda buffer as a control. (Box repre-
sents 25% and 75% quartiles, bar represents median and 
error bars represent range. Mean cfu mL-1 value shown by 
black triangle).
Box Whisker statistical analysis of the viable count data  achieved in relation to the antimicrobial activities of PRE  alone and in combination with Cu(II) ions after a 2 hour incu- bation against 10 clinical isolates of MSSA using Lambda  buffer as a control Figure 2
Box Whisker statistical analysis of the viable count 
data achieved in relation to the antimicrobial activi-
ties of PRE alone and in combination with Cu(II) ions 
after a 2 hour incubation against 10 clinical isolates of 
MSSA using Lambda buffer as a control. (Box repre-
sents 25% and 75% quartiles, bar represents median and 
error bars represent range. Mean cfu mL-1 value shown by a 
black triangle).BMC Complementary and Alternative Medicine 2009, 9:23 http://www.biomedcentral.com/1472-6882/9/23
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Discussion
The antimicrobial effects of pomegranate extracts have
been well publicised over the last decade [8-10,15,17]. A
small number of studies have investigated whether the
antimicrobial properties of extracts, such as PRE, can be
enhanced with the addition of metal salts [14,15,18].
Stewart and colleagues [14] demonstrated that the combi-
nation of PRE and ferrous sulphate could be used a part of
a rapid detection for tuberculosis. A recent study by Sivas-
ankaran-Nair and Selwin-Joseyphus demonstrated the
antimicrobial effects of vanillin extract (an extract of
vanilla) complexes with a number of different metal salts
[18]. The antimicrobial activity of these combinations was
determined by agar diffusion and results showed the most
active complex to be vanillin and copper against the test
organisms (S. aureus, E. coli, K. pneumoniae, P. vulgaris, P.
aeruginosa and Candida albicans).
The aim of this study was to extend our previous work to
investigate the combination of PRE/CuSO4 and vitamin C
against a range of clinical isolates of S. aureus. Initially the
assay was performed as in our previous study with an
incubation time of 30 minutes [15]; however, little to no
antimicrobial activity was seen against the MSSA isolates.
Therefore the incubation of the bacteria with the PRE/
CuSO4 combination was extended and an optimum time
of two hours was determined (data not shown). Against
all isolates of S. aureus the PRE alone gave results similar
to the results of the blank sample (Figures 1, 2 and 3),
demonstrating that over the two hour time period the PRE
did not affect the bacteria. Although, in this study, the PRE
alone did not appear to affect the bacteria, a previous
study has demonstrated that PRE does show an antimicro-
bial activity against a range of bacteria including MRSA
[12]. Challenging different types of MRSA with cupric sul-
phate produced a reduction in cfu mL-1 of between 2 to 3
log10 (Figures 1, 2 and 3). The combination of PRE/Cu(II)
resulted in a further reduction of a log10, compared to the
Cu(II) on its own (Figures 1, 2 and 3). The addition of
vitamin C to the PRE/CuSO4  combination did not
improve the antimicrobial properties of the combination
against any of the S. aureus isolates tested in line with pre-
vious observations.
The individual MIC values of PRE and Cu(II) were deter-
mined for each isolate and the MIC of PRE on its own was
found to vary between 12.5 to 25 mg mL-1. These results
are similar to those reported by Prashanth et al. [17] who
recorded MIC values of 25 mg mL-1 against  S. aureus.
However, other studies have reported lower MIC values
ranging from 0.5–2 mg mL-1 [7,19] and up to up to 250
mg mL-1 against S. aureus [11]. These differences could be
due to the extraction method, freshness of the fruit, sea-
son and region of its growth. The MIC for CuSO4 from this
study varied between 0.78–3.12 mg mL-1; Arestrup and
Hasman [20] determined the MIC of CuSO4 against S.
aureus to be between 2–12 mM. These differences in the
MIC values for CuSO4 may be due to the different strains
of S. aureus used. When the MIC combination of PRE and
CuSO4 was determined it was found that the MIC of both
Table 2: Minimum inhibition concentration of PRE and CuSO4 
alone and in combination against ten isolates each of MRSA, 
MSSA and Panton-Valentine Leukocidin positive CA-MSSA.
Isolates type No. of isolates MIC (mg/mL)
PRE CuSO4 *PRE/CuSO4
MRSA 1 12.5 3.125 6.25/1.563
1 25 1.563 6.25/0.781
2 25 3.125 12.5/1.563
3 25 1.563 12.5/0.781
2 12.5 1.563 6.25/0.781
1 12.5 1.563 6.25/0.781
MSSA 1 25 1.563 6.25/0.391
3 25 1.563 12.5/0.781
1 25 3.125 6.25/0.781
1 12.5 1.563 3.125/0.391
1 12.5 0.782 3.125/0.196
3 12.5 1.563 6.25/0.781
PVL 3 25 1.563 6.25/0.391
4 25 3.125 6.25/0.781
2 25 0.781 6.25/0.195
1 25 1.563 12.5/0.781
*For the PRE/CuSO4 combinations the fixed ratio for each 
component is maintained as shown.
Box Whisker statistical analysis of the viable count data  achieved in relation to the antimicrobial activities of PRE  alone and in combination with Cu(II) ions after a 2 hour incu- bation against 10 clinical isolates of PVL positive CA-MSSA  using Lambda buffer as a control Figure 3
Box Whisker statistical analysis of the viable count 
data achieved in relation to the antimicrobial activi-
ties of PRE alone and in combination with Cu(II) ions 
after a 2 hour incubation against 10 clinical isolates of 
PVL positive CA-MSSA using Lambda buffer as a 
control. (Box represents 25% and 75% quartiles, bar repre-
sents median and error bars represent range. Mean cfu mL-1 
value shown by a black triangle).Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Complementary and Alternative Medicine 2009, 9:23 http://www.biomedcentral.com/1472-6882/9/23
Page 6 of 6
(page number not for citation purposes)
PRE and CuSO4 decreased by a factor of one half (i.e. PRE
decreasing from 12.5 mg mL-1 to 6.25 mg mL-1).
Conclusion
In conclusion, PRE in combination with Cu(II) ions
exhibits additive antimicrobial effects against three classes
of S. aureus. For MSSA, MRSA and PVL positive CA-MSSA
isolates, moderate antimicrobial activities were exhibited
by the mixture. The results of this study suggest that fur-
ther investigations into the active ingredients, the mode of
action and potential synergism with other antimicrobials
are warranted. This is the first report of the efficacy of
pomegranate against PVL positive CA-MSSA isolates.
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